Intelligent Bio Solutions (Intelligent Bio Solutions) Risk Assessment

View and export this data going back to 2020. Start your Free Trial

What is Intelligent Bio Solutions Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Intelligent Bio Solutions is: No Data: Cannot be evaluated.

Competitive Comparison of Intelligent Bio Solutions's Risk Assessment

For the Medical Devices subindustry, Intelligent Bio Solutions's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intelligent Bio Solutions's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Intelligent Bio Solutions's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Intelligent Bio Solutions's Risk Assessment falls into.

Intelligent Bio Solutions (NAS:INBS) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Intelligent Bio Solutions Risk Assessment Related Terms

Thank you for viewing the detailed overview of Intelligent Bio Solutions's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Intelligent Bio Solutions (Intelligent Bio Solutions) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Intelligent Bio Solutions Inc (NAS:INBS) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

12Q:Germany

Address

57th Street, 142 West, 11th Floor, New York, NY, USA, 10019

Website

https://www.gbs.inc

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana.

Executives

Harry Simeonidis	director, officer: CEO, President	708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Foundation Ma-ran	10 percent owner	1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
Gary W. Rollins Foundation	10 percent owner	1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
David A Jenkins	director	P.O. BOX 682838, PARK CITY UT 84068
Jason Isenberg	director	1908 CLIFF VALLEY WAY NE, ATLANTA GA 30329
Spiro Kevin Sakiris	officer: Chief Financial Officer	708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Life Science Biosensor Diagnostics Pty Ltd	10 percent owner	LEVEL 9, 85 CASTLEREAGH STREET, SYDNEY C3 2000
Tom Parmakellis	director	708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Victoria Gavrilenko	director	708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
Christopher Towers	director	1981 MARCUS AVENUE, SUITE 130, LAKE SUCCESS NY 11042
Lawrence B Fisher	director	C/0 FINANCIAL FEDERAL CORP, 733 THIRD AVENUE, NEW YORK NY 10017
Leonard Victor Kempler	director	708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
George Margelis	director	708 THIRD AVENUE, 6TH FLOOR, NEW YORK CITY NY 10017
Boyages Steven Constantine	director	708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017
Jonathan Scott Hurd	director	708 THIRD AVENUE,, 6TH FLOOR, NEW YORK CITY NY 10017